var data={"title":"Interactive diabetes case 16: A 61-year-old man with uncontrolled type 2 diabetes on two oral agents - A1","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Interactive diabetes case 16: A 61-year-old man with uncontrolled type 2 diabetes on two oral agents - A1</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/interactive-diabetes-case-16-a-61-year-old-man-with-uncontrolled-type-2-diabetes-on-two-oral-agents-a1/contributors\" class=\"contributor contributor_credentials\">Lloyd Axelrod, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/interactive-diabetes-case-16-a-61-year-old-man-with-uncontrolled-type-2-diabetes-on-two-oral-agents-a1/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 17, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">ANSWER</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Incorrect.</p><p>In general, the addition of a third oral antidiabetic agent in a patient with a glycated hemoglobin (A1C) value of 9.2 percent is unlikely to achieve the goal of reducing the A1C to &lt;7.0 percent. <a href=\"topic.htm?path=pioglitazone-drug-information\" class=\"drug drug_general\">Pioglitazone</a>, a thiazolidinedione, is a peroxisome proliferator-activated receptor gamma (PPAR-gamma) modulator. It reduces the A1C value by 1.0 to 1.6 percent when used as monotherapy. It is unlikely to reduce the A1C by more than this in a patient who is uncontrolled on two other oral agents. (See <a href=\"topic.htm?path=management-of-persistent-hyperglycemia-in-type-2-diabetes-mellitus#H7554297\" class=\"medical medical_review\">&quot;Management of persistent hyperglycemia in type 2 diabetes mellitus&quot;, section on 'Dual agent failure'</a>.)</p><p>The thiazolidinediones are difficult to use because their effect on glucose levels and A1C values may not be apparent for two to three months. They are expensive. The use of three oral agents is often more expensive than insulin plus <a href=\"topic.htm?path=metformin-drug-information\" class=\"drug drug_general\">metformin</a> when a less expensive insulin such as NPH is used. These agents cause weight gain and fluid retention and increase the risk of congestive heart failure. They should not be used in patients with a history of congestive heart failure or renal insufficiency. <a href=\"topic.htm?path=pioglitazone-drug-information\" class=\"drug drug_general\">Pioglitazone</a> causes an increased risk of fractures of the upper arms, hands, and feet in female diabetic patients. <a href=\"topic.htm?path=rosiglitazone-drug-information\" class=\"drug drug_general\">Rosiglitazone</a>, another agent in the same class, may cause an increased risk of myocardial infarction. For all these reasons, thiazolidinediones are not recommended for the treatment of diabetes. (See <a href=\"topic.htm?path=thiazolidinediones-in-the-treatment-of-diabetes-mellitus#H8\" class=\"medical medical_review\">&quot;Thiazolidinediones in the treatment of diabetes mellitus&quot;, section on 'Cardiovascular effects'</a>.)</p><p>Return to the beginning to try again. (See <a href=\"topic.htm?path=interactive-diabetes-case-16-a-61-year-old-man-with-uncontrolled-type-2-diabetes-on-two-oral-agents\" class=\"medical medical_review\">&quot;Interactive diabetes case 16: A 61-year-old man with uncontrolled type 2 diabetes on two oral agents&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 4210 Version 5.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H1\" id=\"outline-link-H1\">ANSWER</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=interactive-diabetes-case-16-a-61-year-old-man-with-uncontrolled-type-2-diabetes-on-two-oral-agents\" class=\"medical medical_review\">Interactive diabetes case 16: A 61-year-old man with uncontrolled type 2 diabetes on two oral agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-persistent-hyperglycemia-in-type-2-diabetes-mellitus\" class=\"medical medical_review\">Management of persistent hyperglycemia in type 2 diabetes mellitus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=thiazolidinediones-in-the-treatment-of-diabetes-mellitus\" class=\"medical medical_review\">Thiazolidinediones in the treatment of diabetes mellitus</a></li></ul></div></div>","javascript":null}